6281-64-7

Usage

Classification

Thiourea derivative
A compound derived from thiourea, which is a chemical compound containing a thiocarbonyl group (C=S) bonded to two amino groups (NH2).

Usage as a reagent

Organic synthesis
1-Benzoyl-3-[p-(dimethylamino)phenyl]thiourea is often used as a reagent in organic synthesis, aiding in the formation of new chemical bonds and creation of more complex molecules.

Usage as a pharmaceutical intermediate

Drug development
1-Benzoyl-3-[p-(dimethylamino)phenyl]thiourea serves as an intermediate in the production of pharmaceuticals, helping to create more complex and effective drugs.

Pharmacological properties

Antitumor effects
1-Benzoyl-3-[p-(dimethylamino)phenyl]thiourea has been studied for its potential to inhibit or prevent the growth of tumors, showing promise as a possible cancer treatment.

Pharmacological properties

Anti-inflammatory effects
The compound has also been researched for its potential to reduce inflammation, which could be beneficial in treating various inflammatory conditions.

Application in the preparation of organic compounds

Dyes and pharmaceuticals
1-Benzoyl-3-[p-(dimethylamino)phenyl]thiourea is used in the production of various organic compounds, including those used in the manufacturing of dyes and pharmaceuticals.

Potential use as a corrosion inhibitor

Protection against corrosion
The compound has been investigated for its ability to prevent or slow down corrosion, which could be useful in various industries and applications.

Potential treatment for certain medical conditions

Therapeutic applications
1-Benzoyl-3-[p-(dimethylamino)phenyl]thiourea is being studied for its possible use in treating specific medical conditions, although further research is needed to determine its effectiveness.

InChI:InChI=1/C16H17N3OS/c1-19(2)14-10-8-13(9-11-14)17-16(21)18-15(20)12-6-4-3-5-7-12/h3-11H,1-2H3,(H2,17,18,20,21)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 98-88-4 benzoyl chloride 
• 14002-51-8 4-biphenyl-carboxylic acid chloride 
• 99-98-9 4-amino-N,N-dimethylaniline 
• 532-55-8 Benzoyl isothiocyanate 

Downstream Products

• 22283-43-8 1-(4-Dimethylaminophenyl)-thioharnstoff 

Relevant academic research and scientific papers

Synergism of fused bicyclic 2-aminothiazolyl compounds with polymyxin B against: Klebsiella pneumoniae

A series of fused bicyclic 2-aminothiazolyl compounds were synthesized and evaluated for their synergistic effects with polymyxin B (PB) against Klebsiella pneumoniae (SIPI-KPN-1712). Some of the synthesized compounds exhibited synergistic activity. When 4 μg ml-1 compound B1 was combined with PB, it showed potent antibacterial activity, achieving 64-fold reduction of the MIC of PB. Furthermore, compound B1 showed prominent synergistic efficacy in both concentration gradient and time-kill curves in vitro. In addition, B1 combined with PB also exhibited synergistic and partial synergistic effect against E. coli (ATCC25922 and its clinical isolates), Acinetobacter baumannii (ATCC19606 and its clinical isolates), and Pseudomonas aeruginosa (Pae-1399).

Antitubercular activities of the novel synthesized 1,2,4-triazole derivatives

1,2,4-Triazoles exert antimycobacterial activity by inhibiting the cell wall biosynthesis. In an attempt to developing lead compounds exhibiting antitubercular activities, a series of 1,2,4-triazole derivatives were synthesized by introducing various substitutes into a scaffold and the antitubercular activity was evaluated. The most potent compounds 3e and 8d showed their minimum inhibitory concentrations against Mycobacterium tuberculosis as 12.5 ??M. The results indicate that those compounds can be considered as leads for further development of new 1,2,4-triazole type candidates with high antitubercular activities.

Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors

Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole class of SphK inhibitors. Potent inhibitors have been discovered through a series of modifications using the known SKI-II scaffold to define structure-activity relationships. We identified N-(4-methylthiazol-2-yl)-(2,4′-bithiazol)-2′-amine (24, ST-1803; IC50values: 7.3 μM (SphK1), 6.5 μM (SphK2)) as a promising candidate for further in vivo investigations and structural development.

Substituted N-phenylisothioureas: Potent inhibitors of human nitric oxide synthase with neuronal isoform selectivity

S-Ethyl N-phenylisothiourea (4) has been found to be a potent inhibitor of both the human constitutive and inducible isoforms of nitric oxide synthase. A series of substituted N-phenylisothiourea analogues was synthesized to investigate the structure-activity relationship of this class of inhibitor. Each analogue was evaluated for human isoform selectivity. One analogue, S-ethyl N-[4-(trifluoromethyl)phenyl]isothiourea (39), exhibited 115-fold and 29-fold selectivity for the neuronal isoform versus the inducible and endothelial derived constitutive isoforms, respectively. Studies have shown the substituted N-phenylisothiourea 39 binds competitively with L,-arginine.

Improved Procedures for the Preparation of Cycloalkyl-, Arylalkyl-, and Arylthioureas

An improved procedure for the preparation of arylthioureas consists of the reaction of benzoyl isothiocyanate with anilines in acetone and debenzoylation of the resultant N-aryl-N'-benzoylthioureas with 5percent aqueous sodium hydroxide.Bicycloalkylthioureas and N-(arylalkyl)thioureas (e.g. 9H-9-fluorenylthiourea) are directly prepared from the corresponding isothiocyanates and ammonia.